MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call usi ...

Core Insights - Ocugen, Inc. is actively participating in key industry conferences to showcase its advancements in gene therapies for blindness diseases and aims to achieve three Biologics License Applications (BLAs) within the next three years [2][5] Group 1: Conference Participation - Ocugen's executive leadership will present at the 2025 Cell & Gene Meeting on the Mesa, Chardan's 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit [1][4] - Dr. Shankar Musunuri, Chairman and CEO, will engage in discussions about the company's progress and potential partnerships during these events [2][4] - Specific presentation details include: - Cell & Gene Meeting on the Mesa: October 6, 2025, at 4 p.m. MST in Phoenix, AZ [3] - Chardan's 9th Annual Genetic Medicines Conference: October 21, 2025, from 9:30-10:10 a.m. EDT in New York, NY [3] - 2025 Maxim Growth Summit: October 22, 2025, from 3-4 p.m. EDT in New York, NY [4] Group 2: Company Overview - Ocugen is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [5] - The company is developing therapies for inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [5]

Ocugen (NasdaqCM:OCGN) 2025 Conference September 25, 2025 09:30 AM ET Company ParticipantsShankar Musunuri - CEO, Co-founder & Chairman of the BoardHuma Qamar - Chief Medical OfficerNoneWe're good to go. Okay. Good afternoon, and thanks for joining us to have a conversation with Shankar Moussunari, CEO, and Huma Kumar, CFO I mean, CMO of Ocugen. Ocugen is a biotech company focused on discovery, development, and commercializing novel gene and cell therapies. The company's proprietary gene therapy platform ha ...

Group 1 - The author, Sean Daly, specializes in ETFs, biotech, and FINTECH solutions within the banking sector [1] - He has a strong academic background, having taught international finance and financial risk management at Pace University and served as a visiting lecturer at Princeton University [1] - Daly's research interests include diverse topics such as Chinese urbanization, multilateral currency swap arrangements, energy geopolitics, and Asia's sovereign wealth funds [1] Group 2 - The author has a beneficial long position in the shares of OCGN, indicating a personal investment interest [2] - The article reflects the author's own opinions and is not influenced by compensation from any company mentioned [2]

Group 1 - The author, Sean Daly, specializes in ETFs, biotech, and FINTECH solutions within the banking sector [1] - He has a strong academic background, having taught international finance and financial risk management at Pace University and served as a visiting lecturer at Princeton University [1] - Daly's research interests include diverse topics such as Chinese urbanization, multilateral currency swap arrangements, energy geopolitics, and Asia's sovereign wealth funds [1] Group 2 - The author has a beneficial long position in the shares of OCGN, indicating a personal investment interest [2] - The article reflects the author's own opinions and is not influenced by compensation from any company mentioned [2]

Group 1 - The individual is pursuing an MBA and draws inspiration from renowned investors such as Warren Buffett, Peter Lynch, and Terry Smith, focusing on quality companies at reasonable valuations [1] - The belief is that long-term fundamentals drive share prices, with a focus on predicting earnings per share for businesses [1]

Group 1 - Ocugen's stock rose by over 12% following a licensing agreement with Kwangdong Pharmaceutical, significantly outperforming the S&P 500's 0.5% increase [1] - The licensing deal grants Kwangdong exclusive rights to OCU400 in South Korea, targeting retinitis pigmentosa (RP), a retinal disorder causing vision loss [2] - Ocugen will receive up-front fees and development milestones totaling up to $7.5 million, with additional milestones of $1.5 million for every $15 million in sales through Kwangdong [3][4] Group 2 - The potential market for OCU400 in South Korea is significant, with approximately 7,000 people affected by RP, indicating further market opportunities if the drug is commercialized elsewhere [5] - The company stands to earn a 25% royalty on net sales of OCU400 in South Korea, enhancing its revenue potential [4]

Core Viewpoint - Ocugen, Inc. has entered a licensing agreement with Kwangdong Pharmaceutical for exclusive rights to OCU400 in Korea, which is a significant step for the company's growth in the ophthalmology sector [1][4]. Financial Summary - Ocugen will receive upfront license fees and development milestone payments totaling up to $7.5 million, with potential sales milestones projected to exceed $180 million in the first 10 years of commercialization [2]. - The company will earn a royalty of 25% on net sales of OCU400 generated by Kwangdong [2]. Market Potential - There are approximately 7,000 individuals in Korea affected by retinitis pigmentosa, which represents about 7% of the U.S. market for this condition [3]. - OCU400 is positioned as a one-time therapy for patients suffering from retinitis pigmentosa [3]. Development Progress - OCU400 is currently advancing through Phase 3 clinical development, with a target for a U.S. Biologics License Application filing in 2026 [5]. - Kwangdong plans to utilize Ocugen's clinical data for its regulatory submission in Korea [5]. Stock Performance - Following the announcement of the licensing agreement, Ocugen shares rose by 12.15%, closing at $1.20 [5].

Core Viewpoint - Ocugen has entered into a licensing agreement with Kwangdong Pharmaceutical for exclusive rights to OCU400 in Korea, a gene therapy for retinitis pigmentosa, which is expected to significantly impact the treatment landscape for this condition in the region [1][4]. Financial Summary - Ocugen will receive upfront license fees and near-term development milestones totaling up to $7.5 million [2]. - The company is entitled to sales milestones of $1.5 million for every $15 million in sales in Korea, with projected sales reaching $180 million or more in the first 10 years [2]. - A royalty of 25% on net sales of OCU400 generated by Kwangdong will also be received by Ocugen [2]. Market Opportunity - There are approximately 7,000 individuals in South Korea with retinitis pigmentosa, representing about 7% of the U.S. market [3]. - The partnership with Kwangdong is expected to help thousands of patients facing vision loss upon regulatory approval of OCU400 in Korea [3]. Company Profiles - Ocugen is a biotechnology company focused on developing gene therapies for blindness diseases, aiming to address significant unmet medical needs [7]. - Kwangdong Pharmaceutical is a leading healthcare company in Korea, involved in the development and commercialization of pharmaceutical products, with a strong focus on innovation and research [8][9]. Development Status - Ocugen is advancing OCU400 through Phase 3 clinical development, with a target for a U.S. Biologics License Application filing in 2026 [5]. - Kwangdong plans to utilize Ocugen's clinical data and BLA filing for their regulatory submission in Korea [6].

Core Insights - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with upcoming participation in key investment conferences [1][2][4] - Dr. Shankar Musunuri, the CEO, will engage in discussions aimed at expanding the company's visibility and investor relations in the biotech sector [2][4] Conference Details - Dr. Musunuri will participate in the H.C. Wainwright 27 Annual Global Investment Conference from September 8-10, 2025, in New York, with a fireside chat scheduled for September 8 at 5 p.m. ET [3] - The company will also be featured in a panel discussion titled "The FDA Gauntlet: Strategies for a Successful Run at Approval" during Biotech on Tap 2025, taking place from September 24-26, 2025, in Munich, with the panel set for September 25 at 3:30 p.m. CET [3] Company Overview - Ocugen's modifier gene therapy platform aims to address significant unmet medical needs for large patient populations suffering from inherited retinal diseases and other blindness conditions, including retinitis pigmentosa and geographic atrophy [4] - The company's approach is gene-agnostic, targeting complex diseases caused by imbalances in multiple gene networks, differentiating it from traditional gene therapies [4]